MARKET WIREStock Titan • 10h ago
125,000 restricted shares accompany FibroBiologics (FBLG)'s convertible debt offering.Stock Titan report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
Why FBLG Stock advanced +0.21% Today — RQD Quant Desk Flash
$0.93 +0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.93
FibroBiologics Inc. (FBLG) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $6.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on FBLG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.93 (+0.21% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FBLG ranks #658 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does FBLG compare to APRE and XCUR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APRE (Aprea Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for FBLG?
▼
Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $0 in revenue, -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.93 (-0.15%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FBLG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY FBLG SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 36.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.00-6% Next Q
44
Q2 (-2Q)Grade D$0.94+0% Next Q
41
Q3 (-1Q)Grade E$0.94-1.1% Next Q
39
CurrentGrade D-$0.93-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a FBLG Turnaround Squeeze
While FBLG currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.30) and Max Pain ($0.98) forces dealer call-delta covering toward $10.08.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FBLG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FBLG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FBLG Stock advanced +0.21% Today — RQD Quant Desk Flash
FibroBiologics Inc. (FBLG) advanced +0.21% to $0.93, trading at 3% of its 52-week range ($0.62 – $9.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.62 – $9.6) with RSI-14 at 36.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live FBLG Headlines & Catalysts
MARKET WIREInvesting.com Canada • 13h ago
FibroBiologics files patent for cell-based peptide delivery By Investing.comInvesting.com Canada report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 16h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), CircBenzinga report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 19h ago
FibroBiologics (FBLG) Slips to $0.98 as Shares Test Lower Support Zone - Skew Indexhttps://www.siam.in/ report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 22h ago
FibroBiologics, Inc. SEC Filing (Oct 20, 2026)Stock Titan report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
FibroBiologics (FBLG) Slips 2.90% to $0.97, Testing Support Near $0.92 - Conversion Tradehttps://www.dars.gov.et/ report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A 15% discount accompanies FibroBiologics (FBLG)'s zero-interest debt deal.Stock Titan report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
FibroBiologics (FBLG) Slips to $0.96 as Shares Test Key Support Zone - Wave Equalityhttps://www.siam.in/ report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 14d ago
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual MeetingFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
MARKET WIREBenzinga • 14d ago
FibroBiologics Reports Preclinical Data Showing FSdC Spheroids Best Preserve Disc Height In Rabbit Degenerative Disc Disease ModelFSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based Approach Tested in a 12-Week Rabbit Model of Degenerative Disc DiseaseHOUSTON, Oct. 19, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG)
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FBLG)
- ✓Walkthrough of FBLG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FBLG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.61%🛡️ HOLDING TREND SUPPORT
2026-11-02O $0.97H $0.97L $0.93C $0.93VOL 18.1K
RES: $2.89SUP: $0.92SMA50: $1.30SMA200: $2.35
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FBLG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on FBLG today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FBLG. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FBLG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FBLG)
Health Care Rank #658 of 1016
⚔️ APRE vs FBLG Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FBLG vs. APRE, XCUR, ENVB, ACXP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, FibroBiologics Inc. (FBLG) ranks #658 by composite RQD confidence (36/100, grade D-) and #924 by equity capitalization ($6.3M). Within this direct 5-issuer industry benchmark cohort, FBLG leads on earnings valuation at N/A trailing P/E, while FBLG leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with FBLG at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FBLG
ACTIVE
FibroBiologics Inc. | D- | 36/100 | — | — | -35.0% | +0.21% | $6.3M | Benchmark Subject |
| APRE Aprea Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -1.82% | $6.2M | /apre-vs-fblg → |
| XCUR Exicure Inc. | E | 32/100 | — | — | -35.0% | +8.05% | $6.1M | /xcur-vs-fblg → |
| ENVB Enveric Biosciences Inc. | E | 34/100 | — | — | -35.0% | -2.06% | $6.5M | /envb-vs-fblg → |
| ACXP Acurx Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -2.80% | $5.9M | /acxp-vs-fblg → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001958777In its most recent audited fiscal period (FY2025, filed 2025-12-31), FibroBiologics Inc. (FBLG) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$18.6M, operating cash flow of -$16.4M, and free cash flow of -$16.7M (-37.8% YoY). On the balance sheet, FBLG closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$18.6M | -$16.4M | -$16.7M | $9.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$11.2M | -$11.9M | -$12.1M | $16.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$16.5M | -$6.4M | -$6.4M | — | — |
3. FBLG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.93 (+0.21% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FBLG ranks #658 in composite RQD confidence.
How does FBLG compare to APRE and XCUR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APRE (Aprea Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FBLG?
Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $0 in revenue, -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FBLG trading relative to its 50-day, 200-day, and 52-week technical levels?
FBLG last traded at $0.93 (+0.21% on volume of 20,677 shares), positioning the stock -28.46% below its 50-day simple moving average ($1.30) and -60.43% below its 200-day simple moving average ($2.35). Across its 52-week range of $0.62 to $9.60, FBLG sits at the 3.5% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).
FBLG Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is FBLG stock moving today?
Why FBLG Stock advanced +0.21% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
FBLG — FibroBiologics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:43Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, FBLG scores 36 out of 100, a letter grade of D- under the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across its five pillars: Fundamental Cash Engine scores 8/20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns or free cash flow. Whale 13F Flow scores 3/20 on institutional accumulation and options positioning, the weakest pillar, and the source provides no further 13F detail. Insider Conviction scores 5/20 on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10/20 with Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 10/20, reflecting Altman Z 2.5, Piotroski F 2/9, and Debt/Equity 0.5. For a prospective investor, the rating frames a stock with negative operating economics, weak institutional and insider signals, and a balance sheet the rating characterizes as vulnerable. Any upside case would have to rest on factors outside the reported fundamentals, and the source data does not identify such drivers. Valuation tradeoffs are not assessable from the sources because P/E and EV/EBITDA are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-16.6M | $-18.6M | N/A | $-16.7M | $4.9M | N/A |
| FY 2024 | $0.0M | $-13.7M | $-11.2M | N/A | $-12.1M | $14.0M | N/A |
| FY 2023 | $0.0M | $-8.9M | $-16.5M | N/A | $-6.4M | N/A | N/A |
Per the SEC financials, the company reported operating losses in each period shown, with gross, operating, and net margins all at 0%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 2.5, with a Piotroski F-Score of 2/9. Reported cash declined from $14.0M in FY 2024 to $4.9M in FY 2025. Debt/Equity is 0.5 per the Roarable RQD rating, while period-level debt values are not available in source data.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the most recent items reference a 125,000 restricted-share package tied to a convertible debt offering, a patent filing for cell-based peptide delivery, and an SEC filing dated October 20, 2026. Multiple headlines describe the share price slipping to $0.98 and $0.97 and testing support zones near $0.92. These items are tagged as YELLOW light and MARKET WIRE impact. Risk watch items per the sources include the convertible debt financing, which the headline ties to restricted share issuance, and the continued price weakness. The Butterfly Supply-Chain Graph lists no proprietary signals and no butterfly links.
Open Questions
- What are the terms of the convertible debt offering, and how does the 125,000 restricted-share package affect dilution given a $6.3M market capitalization?
- What is the company's cash runway given reported cash of $4.9M against FY 2025 operating income of $-16.6M?
- What clinical or regulatory milestones, if any, are referenced in the patent and SEC filing items, and their timing?
- What is the composition of the institutional, insider, and Congressional flow underlying the 3/20 and 5/20 pillar scores?
- Why are period-level debt and EPS values unavailable, and how was the Debt/Equity ratio of 0.5 derived?
FBLG Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for FibroBiologics Inc. (FBLG) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 10h ago
125,000 restricted shares accompany FibroBiologics (FBLG)'s convertible debt offering. Stock Titan report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Canada • 13h ago
FibroBiologics files patent for cell-based peptide delivery By Investing.com Investing.com Canada report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 16h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), Circ Benzinga report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 19h ago
FibroBiologics (FBLG) Slips to $0.98 as Shares Test Lower Support Zone - Skew Index https://www.siam.in/ report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 22h ago
FibroBiologics, Inc. SEC Filing (Oct 20, 2026) Stock Titan report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
FibroBiologics (FBLG) Slips 2.90% to $0.97, Testing Support Near $0.92 - Conversion Trade https://www.dars.gov.et/ report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 15% discount accompanies FibroBiologics (FBLG)'s zero-interest debt deal. Stock Titan report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
FibroBiologics (FBLG) Slips to $0.96 as Shares Test Key Support Zone - Wave Equality https://www.siam.in/ report covering FibroBiologics Inc. (FBLG) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
FBLG Bull vs. Bear Conversation Board — What's Your Call at $0.93?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FBLG 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.82 (-11.8%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is FBLG (D- • RQD 36/100) a Buy at $0.93?
Welcome to the FBLG (FibroBiologics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.73 (-21.5%)
Spot @ $0.93 Pump the brakes on FBLG — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on FBLG, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless FibroBiologics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.12 (+20.4%)
Spot @ $0.93 FBLG cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on FBLG, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.93 (52-wk range $0.62 - $9.60), any beat on forward guidance forces shorts and underweight funds to chase.